Sponsored Links
| Human Genome Sciences Submits Biologics License Application To FDA For ZALBIN™ |
 |
 |
 |
| Medical News - Liver Disease and Hepatitis | |||
|
Human Genome Sciences, Inc. (Nasdaq: HGSI) announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C... Read more: Liver Disease / Hepatitis News From Medical News Today
|